The Pharmacovigilance program in Nepal is at very preliminary stage. Present study analyzed the pattern, causality, severity and preventability of the reported adverse drug reactions (ADRs) to the Pharmacovigilance center at Nepal Medical College and Teaching Hospital (NMCTH), from June 2007 to July 2011. A total of 40 ADR cases were reported, among which 23 (57.5%) were in males and 17 (42.5%) in females. Nineteen (47.5%) ADRs were reported in the age group between 21-40 years. Department of Medicine reported 12(30%) ADRs. Among the total ADRs, antibiotics [n=17, (42.5%)] were responsible for most of the reactions followed by non steroidal anti-inflammatory drugs [n=5, (12.5%)]. Most of the drugs were found to affect dermatological system [n=14, (35%)]. Carbamazepine accounted for 5 (12.5%) ADRs. The causality assessment showed 34 (85%) of the ADRs to have a 'probable' relationship with the suspected reaction.
Introduction
Harmful, unintended reactions to medicines that occur at doses normally used for treatment are called adverse drug reactions (ADRs). ADRs are among the leading causes of death in many countries [1] . A survey from Canada observed that 19% (162, n= 863) of the admissions exhibited at least one drug-related adverse patient event at the time of hospitalization. During the study ADRs were responsible for many drug-related adverse events (48%) [2] .
A multicentric study conducted on Nepal revealed that 0.64% of the hospital admissions were related to drugs [3] . Similarly, another study conducted in different hospitals of Nepal revealed the prevalence of 0.86% of ADR from 4287 patients studied for 5 months [4] . Drug related complications are often ignored in developing countries like ours. People often put their lives at risk as they do not know the consequences of irrational drug use without proper patient counseling and expert advices. Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems. Recently, it also includes herbals, traditional and complementary medicines, blood products, biologicals, medicinal devices and vaccines as well [5] .
Till now there is lack of reports on the incidence of ADRs in Nepal and we have to rely totally on data from other countries. Pharmacology at NMCTH has been coordinating as a Pharmacovigilance center, to collected the suspected ADRs from all the departments. Therefore the present study was carried out to find out the pattern of the adverse drug reactions reported to the center as well as to carry out the causality, severity, and preventability of the reported adverse drug reactions.
Materials and Methods
Study Design: A cross sectional study evaluating the pattern of ADRs. Study site: Nepal Medical College and Teaching Hospital, Jorpati Kathmandu, Nepal. Tools: Adverse drug reaction reporting form designed by the Pharmacovigilance center, NMCTH All ADRs reported to the PV center of NMCTH since June 2007 to July 2011 were documented. Health care professionals (Medical Doctors, Nurses, Medical Students and Pharmacists) were briefed about the process of reporting ADRs. Follow-up visits were made to different wards to encourage reporting ADRs. Each and every reported case was thoroughly revised and necessary information was gathered from the patient's chart from Medical record section of the hospital. All cases were analyzed for the Causality, Severity and Preventability as per the Naranjo, Hartwig and Modified Schumock and Thronton scales respectively. Few of these cases have also been reported to DDA via Vigiflow software. DDA then sends those reports to Uppsala Monitoring center (UMC), Sweden: a WHO recognized international center for ADR reporting.
Results
During four years of time, pharmacovigilance center at NMCTH received a total of 40 ADRs. The results were as follows Similarly, the severity assessment found 12 (30%) ADRs to be of 'moderate (level 3)', 11 (27.5%) to be 'mild (level 1)', 7 (17.5%) to be of 'mild (level 2) and 'moderate (level 4(a))' respectively, 2 (5%) to be 'moderate level 4(b)' and finally 1 (2.5%) ADR was of 'severe level (5)' type. The preventability assessment showed, 35 (87.5%) ADRs to be 'Non Preventable', while 5 (12.5%) ADRs were of 'probably preventable' type. 
Discussion
Our study analyses the pattern, causality, severity and preventability of the ADRs reported since July 2007 to July 2011, to the regional Pharmacovigilance center at NMC.
Out of 40 ADR cases, 57.5 % (n=23) were found among males and 42.5 % (n=17) in females.
Other studies however have shown females to be more prone to ADRs than males [6, 7] . Small study population of our study might have influenced this result of the study.
Our study found maximum number 47.5% (n=19) of patients suffering from ADRs between the age groups of 21-40 years. The result is similar to the findings in the study by Subish et al conducted in Nepal [8] and by Martin et al as well [7] . We found antibiotics were responsible for majority 42.5% (n=17) of ADRs followed by nonsteroidal anti-inflammatory drugs (NSAIDS) 12.5% (n=5), antihypertensive 12.5% (n=5), antiepileptic 12.5% (n=5), antiviral 10% (n=4), antipsychotic 7.5% (n=3), and antileprotic 2.5% (n=1) respectively. Our result is similar to the findings of study by Subish et al and Jha et al in Nepal. [4, 9] Dermatological system n=14(35%) was the most common organ system followed by hematological system n=8(20%) and this finding is consistent with the reports of an Indian study [10] . The causality assessment revealed that most of the ADRs belonged to "probable" n=34 (85%) followed by possible n=5(12.5%) and definite n=1(2.5%). Upon severity assessment Moderate (level 3) type accounted for n=12(30%) of the reports. The ADR requires that the suspected drug be withheld, discontinued otherwise changed, and/or on antidote or other treatment is required.
There is no increase in length of stay due to ADR. 
Conclusion
Pharmacovigilance related activities needs to be strengthened in Nepal with the active participation of health care professionals. There has to be regular training programs on Pharmacoviliance. National Pharmacovigilance center should take an initiative for this noble effort.
